← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
ATNM
Actinium Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 43 · Elevated
Price$1.28
Model IV—
P/IV—
Market implies +89.9%/yr vs model +2.0% · above model
ATOM
Atomera Inc
Valuation N/A
Technology Risk 42 · Elevated
Price$4.15
Model IV—
P/IV—
Market implies +133.6%/yr vs model +2.0% · above model
ATOS
ATOSSA THERAPEUTICS, INC.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$2.48
Model IV—
P/IV—
Limited data — see page
ATS
ATS Corp /ATS
Valuation N/A
Industrials Risk 32 · Moderate
Price$19.20
Model IV—
P/IV—
Limited data — see page
ATYR
aTYR PHARMA INC
Valuation N/A
Healthcare Risk 26 · Moderate
Price$0.39
Model IV—
P/IV—
Market implies +82.5%/yr vs model +15.0% · above model
AUC
ATIF Holdings Ltd
Valuation N/A
Industrials Risk 27 · Moderate
Price$7.15
Model IV—
P/IV—
Market implies +107.1%/yr vs model +2.0% · above model
AUGO
Aura Minerals Inc.
Valuation N/A
Basic Materials Risk 48 · Elevated
Price$87.08
Model IV—
P/IV—
Limited data — see page
AUNA
AUNA S.A.
Valuation N/A
Healthcare
Price$5.17
Model IV—
P/IV—
Limited data — see page
AUR
Aurora Innovation, Inc.
Valuation N/A
Technology Risk 37 · Moderate
Price$6.43
Model IV—
P/IV—
Market implies +150.0%/yr vs model +2.0% · above model
AURA
Aura Biosciences, Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$7.00
Model IV—
P/IV—
Limited data — see page
AURE
Aurelion Inc.
Valuation N/A
Financial Services Risk 46 · Elevated
Price$1.44
Model IV—
P/IV—
Market implies +41.0%/yr vs model +2.0% · above model
AUROW
Aurora Innovation, Inc.
Valuation N/A
Technology Risk 37 · Moderate
Price$0.07
Model IV—
P/IV—
Market implies +57.2%/yr vs model +2.0% · above model
AUST
Austin Gold Corp.
Valuation N/A
Basic Materials Risk 30 · Moderate
Price$1.15
Model IV—
P/IV—
Limited data — see page
AUTL
Autolus Therapeutics plc
Valuation N/A
Healthcare Risk 36 · Moderate
Price$1.94
Model IV—
P/IV—
Market implies +34.2%/yr vs model +15.0% · above model
AUUD
AUDDIA INC.
Valuation N/A
Technology Risk 43 · Elevated
Price$0.98
Model IV—
P/IV—
Limited data — see page
AVAL
Grupo Aval Acciones Y Valores S.A.
Valuation N/A
Financial Services Risk 31 · Moderate
Price$5.35
Model IV—
P/IV—
Limited data — see page
AVAV
AeroVironment Inc
Valuation N/A
Industrials Risk 42 · Elevated
Price$146.71
Model IV—
P/IV—
Market implies +24.2%/yr vs model +20.1% · above model
AVBP
ArriVent BioPharma, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$28.57
Model IV—
P/IV—
Limited data — see page
AVEX
AEVEX Corp.
Valuation N/A
Industrials Risk 46 · Elevated
Price$16.08
Model IV—
P/IV—
Limited data — see page
AVGO
Broadcom Inc.
Valuation N/A
Technology Risk 28 · Moderate
Price$339.27
Model IV—
P/IV—
Market implies +31.9%/yr vs model +23.5% · above model
AVIR
Atea Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$5.31
Model IV—
P/IV—
Market implies -2.4%/yr vs model +15.0% · below model
AVK
ADVENT CONVERTIBLE & INCOME FUND
Valuation N/A
Unknown
Price$12.23
Model IV—
P/IV—
Limited data — see page
AVLN
Avalyn Pharma Inc.
Valuation N/A
Healthcare Risk 51 · Elevated
Price$33.57
Model IV—
P/IV—
Limited data — see page
AVR
Anteris Technologies Global Corp.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$8.35
Model IV—
P/IV—
Market implies +117.9%/yr vs model +2.0% · above model
AVTX
Avalo Therapeutics, Inc.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$16.12
Model IV—
P/IV—
Market implies +142.3%/yr vs model +2.0% · above model
AVX
AVAX ONE TECHNOLOGY LTD.
Valuation N/A
Financial Services Risk 29 · Moderate
Price$3.93
Model IV—
P/IV—
Market implies +150.0%/yr vs model +27.8% · above model
AVXL
ANAVEX LIFE SCIENCES CORP.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$2.44
Model IV—
P/IV—
Limited data — see page
AVY
Avery Dennison Corp
Valuation N/A
Basic Materials Risk 40 · Elevated
Price$169.38
Model IV—
P/IV—
Market implies +5.2%/yr vs model +3.0% · in line
AWF
ALLIANCEBERNSTEIN GLOBAL HIGH INCOME FUND INC
Valuation N/A
Unknown
Price$9.96
Model IV—
P/IV—
Limited data — see page
AWP
abrdn Global Premier Properties Fund
Valuation N/A
Unknown
Price$11.15
Model IV—
P/IV—
Limited data — see page
AXG
Solowin Holdings, Ltd.
Valuation N/A
Financial Services Risk 29 · Moderate
Price$2.13
Model IV—
P/IV—
Market implies +48.8%/yr vs model +2.0% · above model
AXIA
AXIA Energia S.A.
Valuation N/A
Utilities
Price$9.53
Model IV—
P/IV—
Limited data — see page
AXIN
Axiom Intelligence Acquisition Corp 1
Valuation N/A
Financial Services
Price$10.34
Model IV—
P/IV—
Limited data — see page
AXINR
Axiom Intelligence Acquisition Corp 1
Valuation N/A
Financial Services
Price$0.34
Model IV—
P/IV—
Limited data — see page
AXON
AXON ENTERPRISE, INC.
Valuation N/A
Industrials Risk 47 · Elevated
Price$479.34
Model IV—
P/IV—
Market implies +27.2%/yr vs model +34.0% · below model
AXSM
Axsome Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$220.75
Model IV—
P/IV—
Market implies +18.8%/yr vs model +15.0% · above model
AXTI
AXT INC
Valuation N/A
Technology Risk 31 · Moderate
Price$64.77
Model IV—
P/IV—
Market implies +87.2%/yr vs model +2.0% · above model
AYA
Aya Gold & Silver Inc.
Valuation N/A
Basic Materials
Price$27.97
Model IV—
P/IV—
Limited data — see page
AZ
A2Z CUST2MATE SOLUTIONS CORP.
Valuation N/A
Industrials Risk 32 · Moderate
Price$5.79
Model IV—
P/IV—
Limited data — see page
AZI
Autozi Internet Technology (Global) Ltd.
Valuation N/A
Industrials
Price$1.25
Model IV—
P/IV—
Limited data — see page
AZN
ASTRAZENECA PLC
Valuation N/A
Healthcare
Price$160.17
Model IV—
P/IV—
Limited data — see page
AZTA
Azenta, Inc.
Valuation N/A
Industrials Risk 31 · Moderate
Price$30.85
Model IV—
P/IV—
Market implies +34.3%/yr vs model +8.4% · above model
AZTR
Azitra, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.18
Model IV—
P/IV—
Market implies +50.2%/yr vs model +15.0% · above model
AZZ
AZZ INC
Valuation N/A
Industrials Risk 41 · Elevated
Price$132.75
Model IV—
P/IV—
Market implies -2.0%/yr vs model +25.0% · below model
BA
BOEING CO
Valuation N/A
Industrials Risk 46 · Elevated
Price$210.27
Model IV—
P/IV—
Market implies +51.2%/yr vs model +8.0% · above model
BABA
Alibaba Group Holding Ltd
Valuation N/A
Technology Risk 44 · Elevated
Price$109.23
Model IV—
P/IV—
Market implies +31.0%/yr vs model +2.5% · above model
BACC
Blue Acquisition Corp/Cayman
Valuation N/A
Financial Services
Price$10.48
Model IV—
P/IV—
Limited data — see page
BACCR
Blue Acquisition Corp/Cayman
Valuation N/A
Financial Services
Price$0.42
Model IV—
P/IV—
Limited data — see page
BAK
BRASKEM SA
Valuation N/A
Basic Materials Risk 46 · Elevated
Price$2.08
Model IV—
P/IV—
Limited data — see page
BAM
Brookfield Asset Management Ltd.
Valuation N/A
Financial Services Risk 43 · Elevated
Price$46.63
Model IV—
P/IV—
Limited data — see page
BANX
ArrowMark Financial Corp.
Valuation N/A
Unknown
Price$20.97
Model IV—
P/IV—
Limited data — see page
BAP
CREDICORP LTD
Valuation N/A
Financial Services Risk 41 · Elevated
Price$377.90
Model IV—
P/IV—
Limited data — see page
BAR
GraniteShares Gold Trust
Valuation N/A
Financial Services Risk 32 · Moderate
Price$42.16
Model IV—
P/IV—
Limited data — see page
BARK
Bark, Inc.
Valuation N/A
Consumer Cyclical Risk 42 · Elevated
Price$9.59
Model IV—
P/IV—
Market implies +27.4%/yr vs model +6.3% · above model
BAVA
Bitwise Avalanche ETF
Valuation N/A
Financial Services Risk 51 · Elevated
Price$20.28
Model IV—
P/IV—
Limited data — see page
BAYA
Bayview Acquisition Corp
Valuation N/A
Financial Services Risk 32 · Moderate
Price$12.14
Model IV—
P/IV—
Limited data — see page
BAYAR
Bayview Acquisition Corp
Valuation N/A
Financial Services Risk 35 · Moderate
Price$0.08
Model IV—
P/IV—
Limited data — see page
BB
BLACKBERRY Ltd
Valuation N/A
Technology Risk 30 · Moderate
Price$7.67
Model IV—
P/IV—
Market implies +26.8%/yr vs model +2.0% · above model
BBAI
BigBear.ai Holdings, Inc.
Valuation N/A
Technology Risk 42 · Elevated
Price$2.87
Model IV—
P/IV—
Market implies +61.3%/yr vs model +2.0% · above model
BBAR
Banco BBVA Argentina S.A.
Valuation N/A
Financial Services Risk 52 · Elevated
Price$14.89
Model IV—
P/IV—
Limited data — see page